(Q36839925)

16 August 2017

1 reference

title

Prevention of type 2 diabetes: an update (English)

1 reference

16 August 2017

1 reference

Amal Farag

1

1 reference

16 August 2017

Jocelyne Karam

series ordinal

2

1 reference

16 August 2017

John Nicasio

series ordinal

3

1 reference

16 August 2017

Samy I McFarlane

series ordinal

4

1 reference

16 August 2017

publication date

1 June 2007

1 reference

16 August 2017

published in

Current diabetes report

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

200-207

1 reference

Diabetes, hypertension, and cardiovascular disease: an update

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-007-0032-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-007-0032-4

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-007-0032-4

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

12 December 2020

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

12 December 2020

Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia

1 reference

12 December 2020

Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study

1 reference

12 December 2020

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

12 December 2020

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

12 December 2020

Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.

1 reference

12 December 2020

Effects of exercise on insulin sensitivity in humans

1 reference

12 December 2020

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond

1 reference

12 December 2020

Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

1 reference

12 December 2020

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

1 reference

12 December 2020

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

12 December 2020

Effect of ramipril on the incidence of diabetes

1 reference

12 December 2020

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

12 December 2020

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

12 December 2020

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

1 reference

12 December 2020

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

1 reference

12 December 2020

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

12 December 2020

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

1 reference

12 December 2020

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

12 December 2020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

12 December 2020

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers

1 reference

12 December 2020

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

12 December 2020

Gender disparities in the control of cardiovascular risk factors in people with diabetes

1 reference

12 December 2020

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

1 reference

12 December 2020

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

12 December 2020

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

1 reference

12 December 2020

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

12 December 2020

Surgery as an intervention for obesity. Results from the Swedish obese subjects study.

1 reference

12 December 2020

Ramipril and the development of diabetes.

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

Prevention of type 2 diabetes

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

12 December 2020

Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

1 reference

12 December 2020

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

12 December 2020

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

12 December 2020

Economic costs of diabetes in the US in 2002.

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

10.1007/S11892-007-0032-4

Identifiers

DOI

1 reference

16 August 2017

1 reference